The company made the announcement during trading hours today, 27 December 2012.
Meanwhile, the BSE Sensex was up 4.43 points or 0.02% at 19,421.89.
On BSE, 51,000 shares were traded in the counter as against average daily volume of 3.66 lakh shares in the past one quarter.
The stock hit a high of Rs 195.35 and a low of Rs 192.55 so far during the day. The stock had hit a 52-week high of Rs 201.40 on 5 December 2012. The stock had hit a 52-week low of Rs 83.35 on 29 December 2011.
The stock had outperformed the market over the past one month till 26 December 2012, surging 7.88% compared with the Sensex's 4.75% rise. The scrip had also outperformed the market in past one quarter, jumping 37.46% as against Sensex's 4.21% gain.
The mid-cap pharmaceutical company has equity capital of Rs 29.11 crore. Face value per share is Re 1.
Aurobindo Pharma has received final approvals from the US Food and Drug Administration (USFDA) to manufacture and market Nafcillin for Injection USP, packaged in 1g and 2g vials and Nafcillin for Injection USP 10g/Vial Pharmacy Bulk Package. The products are ready for launch, the company said in a statement.
Nafcillin for Injection is a sterile semisynthetic penicillin (SSP) indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. It may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of susceptibility test results, Aurobindo said.
These abbreviated new drug applications (ANDA) have been approved out of Unit XII formulation facility in Hyderabad and will be marketed and sold by Aurobindo's US subsidiary AuroMedics Pharma LLC, the company said.
Aurobindo now has a total of 171 ANDA approvals (145 final approvals including 2 from Aurolife Pharma LLC and 26 tentative approvals) from USFDA.
Aurobindo Pharma reported consolidated net profit of Rs 222.35 crore in Q2 September 2012, compared with net loss of Rs 80.16 crore in Q2 September 2011. Net sales rose 40.9% to Rs 1481.05 crore in Q2 September 2012 over Q2 September 2011.
Aurobindo Pharma, headquartered at Hyderabad in Andhra Pradesh, manufactures generic pharmaceuticals and active pharmaceutical ingredients (APIs). The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics. The company is marketing these products globally, in over 125 countries.
Powered by Capital Market - Live News
